These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18175216)

  • 1. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
    Choi DH; Cho DY; Lee MH; Park HS; Ahn SH; Son BH; Haffty BG
    Breast Cancer Res Treat; 2008 Dec; 112(3):569-73. PubMed ID: 18175216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
    Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
    Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHEK2 1100delC is not a risk factor for male breast cancer population.
    Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
    Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
    Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML
    Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
    Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
    Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.
    Rashid MU; Jakubowska A; Justenhoven C; Harth V; Pesch B; Baisch C; Pierl CB; Brüning T; Ko Y; Benner A; Wichmann HE; Brauch H; Hamann U;
    Eur J Cancer; 2005 Dec; 41(18):2896-903. PubMed ID: 16239104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
    Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
    Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
    de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Aug; 23(4):443-5. PubMed ID: 16883537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
    Rajkumar T; Soumittra N; Nancy NK; Swaminathan R; Sridevi V; Shanta V
    Asian Pac J Cancer Prev; 2003; 4(3):203-8. PubMed ID: 14507240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population.
    Osorio A; Rodríguez-López R; Díez O; de la Hoya M; Ignacio Martínez J; Vega A; Esteban-Cardeñosa E; Alonso C; Caldés T; Benítez J
    Int J Cancer; 2004 Jan; 108(1):54-6. PubMed ID: 14618615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
    Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H
    Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
    Skasko E; Kluska A; Niwińska A; Kwiatkowska E; Bałabas A; Piatkowska M; Dabrowska M; Nowakowska D; Pieńkowski T
    Onkologie; 2009 Apr; 32(4):182-8. PubMed ID: 19372713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
    Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
    Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHEK2 1100delC and male breast cancer in the Netherlands.
    Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
    Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.